Methyl cyanoacetate is a colorless liquid with a pungent odor. It is a versatile building block in organic synthesis, widely used in the production of pharmaceuticals, pesticides, and other fine chemicals. Its synthesis typically involves the reaction of cyanoacetic acid with methanol in the presence of a catalyst like sulfuric acid. Methyl cyanoacetate is known for its ability to undergo a variety of reactions, including alkylation, acylation, and condensation. It is also a key intermediate in the synthesis of numerous heterocyclic compounds. The study of methyl cyanoacetate is driven by its importance in organic synthesis and its potential applications in various industries. Its reactivity and versatility make it an attractive starting material for the development of new and innovative compounds.'
| ID Source | ID |
|---|---|
| PubMed CID | 7747 |
| CHEMBL ID | 1532013 |
| CHEBI ID | 51928 |
| Synonym |
|---|
| smr001261799 |
| MLS002177808 , |
| methyl 2-cyanoacetate |
| cyanoacetic acid, methyl ester |
| usaf kf-22 |
| wln: nc1vo1 |
| 105-34-0 |
| nsc-3113 |
| cyanoacetic acid methyl ester |
| methyl cyanoacetate |
| nsc3113 |
| methyl cyanoethanoate |
| methylester kyseliny kyanoctove [czech] |
| ai3-05599 |
| nsc 3113 |
| brn 0773945 |
| einecs 203-288-8 |
| nsc-68507 |
| nsc68507 |
| acetic acid, cyano-, methyl ester |
| NCGC00090994-01 |
| inchi=1/c4h5no2/c1-7-4(6)2-3-5/h2h2,1h |
| methyl cyanoacetate, 99% |
| malonic methyl ester nitrile |
| CHEBI:51928 , |
| 2-cyanoacetic acid, methyl ester |
| AKOS000118973 |
| NCGC00090994-02 |
| dtxcid6013649 |
| tox21_200938 |
| NCGC00258492-01 |
| cas-105-34-0 |
| dtxsid8033649 , |
| 2-cyanoacetic acid methyl ester |
| (methoxycarbonyl)acetonitrile |
| 3-methoxy-3-oxopropanenitrile |
| STL146530 |
| unii-a28ri36v30 |
| ec 203-288-8 |
| a28ri36v30 , |
| methylester kyseliny kyanoctove |
| acetic acid, 2-cyano-, methyl ester |
| BP-13327 |
| FT-0624127 |
| bdbm74253 |
| methyl 2-cyanoethanoate |
| cid_7747 |
| methyl cyano acetate |
| methyl-cyano-acetate |
| cyano-acetic acid methyl ester |
| 2-cyano-acetic acid methyl ester |
| methylcyanacetate |
| methyl-cyanoacetate |
| ncch2co2ch3 |
| methylcyanoacetate |
| cyano acetic acid methyl ester |
| STR01166 |
| CHEMBL1532013 |
| methyl .alpha.-cyanoacetate |
| j4.029k , |
| J-001390 |
| F0001-0103 |
| mfcd00001939 |
| methyl cyanoacetate, purum, >=99.0% (gc) |
| BCP25864 |
| Q22829041 |
| CS-W016657 |
| D77797 |
| STARBLD0016244 |
| EN300-19214 |
| Class | Description |
|---|---|
| alkyl cyanoacetate ester | An ester of cyanoacetic acid with the general formula N#C-CR(1)R(2)-C(=O)OR(3) where R(3) is an alkyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 28.7563 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 3.5481 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.5157 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 0.3651 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||